<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04872439</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00114555</org_study_id>
    <nct_id>NCT04872439</nct_id>
  </id_info>
  <brief_title>Novel Antineuronal Antibodies in Gastrointestinal Motility Disorders</brief_title>
  <official_title>Novel Antineuronal Antibodies in Gastrointestinal Motility Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastrointestinal motility disorders represent a heterogeneous group of neuromuscular diseases&#xD;
      of the enteric nervous systems. While autoimmune neuromuscular diseases of the central&#xD;
      nervous system (CNS) are well described, the role of autoimmunity in enteric nervous system&#xD;
      (ENS) has been less studied. Approximately 10% of patients with unexplained gastrointestinal&#xD;
      dysmotility diseases have positive serum autoantibodies to peripheral nervous system&#xD;
      proteins, suggesting an autoimmune mechanism targeting the enteric nervous system. The&#xD;
      investigator's aim is to identify novel anti neuronal antibodies that contribute to&#xD;
      autoimmune gastrointestinal motility disorders by analyzing the serum of patients with&#xD;
      abnormal gastrointestinal motility.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antibodies for Autoimmune Gastrointestinal Dysmotility</measure>
    <time_frame>Baseline</time_frame>
    <description>Presence or absence of Autoimmune Gastrointestinal Dysmotility specific antibodies.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Autoimmune Gastrointestinal Dysmotility</condition>
  <arm_group>
    <arm_group_label>Antibody isolation</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sample collection</intervention_name>
    <description>Patients with autoimmune gastrointestinal dysmotility will provide 20 mL of blood to isolate serum, plasma and peripheral blood mononuclear cells for whole exome sequence. Antibodies to be isolated are: Antineuronal nuclear antibody type 1,Collapsing response-mediator family immunoglobulin G, Ganglionic Acetylcholine Receptor Antibody, Muscle Acetylcholine Receptor Antibody, Striational, Voltage-gated calcium channel, N- type, Voltage-gated calcium channel, P/Q- type, Voltage-gated potassium channel, Glutamic Acid Decarboxylase 65, Gastric parietal cell, Thyroperoxidase, Thyroglobulin</description>
    <arm_group_label>Antibody isolation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with autoimmune gastrointestinal dysmotolity&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females &gt;13 years old.&#xD;
&#xD;
          -  Patient referred to the GI Motility clinic for suspected enteric dysmotility based on&#xD;
             chronic refractory gastrointestinal symptoms&#xD;
&#xD;
          -  English proficiency and literacy sufficient to sign consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy documented with a serum or urine pregnancy test. If participants believe&#xD;
             that they are pregnant, they will need to notify a study physician who will order a&#xD;
             serum or urine test for pregnancy and remove them from the study if the test results&#xD;
             come back positive.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pankaj J Pasricha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pankaj J Pasricha, MD</last_name>
    <phone>410-550-1793</phone>
    <email>pasricha@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guillermo A Barahona, MD</last_name>
    <phone>410-603-8343</phone>
    <email>gbaraho1@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pankaj Pasricha, MD</last_name>
      <phone>410-550-1793</phone>
      <email>pasricha@jhu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Guillermo Barahona, MD</last_name>
      <phone>4106038343</phone>
      <email>gbaraho1@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

